Last week, results of a clinical study were released bringing new hope for Alzheimer’s patients: “Our results indicate that treatment of AD patients with CMA (full list) can lead to enhanced cognitive functions and improved clinical parameters associated with phenomics, metabolomics, proteomics and imaging analysis.” While this is clearly encouraging news, we’re quick to defer to the expertise of those better positioned to analyze the study results to tell us what they mean. And there’s no one better than Alzheimer’s expert Dr. Rudy Tanzi — who also happens to be a passionate consumer of one of the CMAs in the latest study, Nicotinamide Riboside “NR” (FAQs) (Reviews).

Who is Dr. Rudy Tanzi?

He’s one of the leading authorities on Alzheimer’s disease.

He’s a Professor of Neurology at Harvard University, Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Co-director of the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital.

He’s also currently involved in a clinical trial studying vitamin supplement NR (again, one of the CMAs in the latest study) in individuals with mild cognitive impairment (MCI) and mild Alzheimer’s dementia (AD). More HERE.

As for his knowledge of NAD+ and NR, look no further than his comments on various recent podcasts:

  • Dr. Tanzi’s explains why he “religiously” takes NR, and how his lab work suggests NR could help reduce risk for Alzheimer’s (Link)
  • Dr. Tanzi explains in great detail why he’s launching a Clinical Trial testing NR for Alzheimer’s (Link)
  • Dr. Oz’s mom has Alzheimers; Her regimen includes NR (Link)
  • Dr. Tanzi convinced the NFL’s New England Patriots to take a daily dose of NR (Link)
  • WebMD: The End of Alzheimer’s; How New Treatments Might Rewrite The Long Goodbye (Link)

So, what does Dr. Tanzi think of the latest Alzheimer’s study results?

In a brief email exchange, here’s what he told us:

The results look very promising and I would predict that the effects of NR on NAD+ played a significant role in the trial.

Dr. Rudy Tanzi

You can take away what you’d like from this comment.

Please note that my question to him was simply asking for his reaction to the latest study results — nothing specific about NAD+ or NR.

Of course, if you read Dr. Tanzi’s various podcast comments linked to above, you can clearly see where Dr. Tanzi stands on the possibilities for NR and Alzheimer’s.

And this study likely did nothing but add to his conviction.

Let’s hope Dr. Tanzi’s trial as well as the upcoming Phase 3 of this latest CMA trial show great results.

NOTE:

FOLLOW us on Twitter @RaisingNAD